Effects of MetAP2 inhibition on hyperphagia and body weight in Prader –Willi syndrome: A randomized, double‐blind, placebo‐controlled trial

Conclusions
MetAP2 inhibition with beloranib produced statistically significant and clinically meaningful improvements in hyperphagia‐related behaviours and weight loss in participants with PWS. Although investigation of beloranib has ceased, inhibition of MetAP2 is a novel mechanism for treating hyperphagia and obesity.

Source: Diabetes, Obesity and Metabolism - July 13, 2017 Category: Endocrinology Authors: Shawn E. McCandless, Jack A. Yanovski, Jennifer Miller, Cary Fu, Lynne M. Bird, Parisa Salehi, Christine L. Chan, Diane Stafford, M. Jennifer Abuzzahab, David Viskochil, Sarah E. Barlow, Moris Angulo, Susan E. Myers, Barbara Y. Whitman, Dennis Styne, Eliz Tags: ORIGINAL ARTICLE Source Type: research